Pacira BioSciences, Valuation
| PCRX Stock | USD 24.14 0.32 1.34% |
At this time, the company appears to be overvalued. Pacira BioSciences, holds a recent Real Value of $21.35 per share. The prevailing price of the company is $24.14. Our model determines the value of Pacira BioSciences, from analyzing the company fundamentals such as Return On Equity of -0.12, operating margin of 0.16 %, and Shares Outstanding of 46.28 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Pacira BioSciences,'s valuation include:
Price Book 1.4162 | Enterprise Value | Enterprise Value Ebitda 43.1533 | Price Sales 1.5937 | Forward PE 8.8028 |
Overvalued
Today
Please note that Pacira BioSciences,'s price fluctuation is not too volatile at this time. Calculation of the real value of Pacira BioSciences, is based on 3 months time horizon. Increasing Pacira BioSciences,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Pacira BioSciences, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pacira Stock. However, Pacira BioSciences,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 24.14 | Real 21.35 | Target 19.29 | Hype 23.9 | Naive 25.17 |
The intrinsic value of Pacira BioSciences,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pacira BioSciences,'s stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pacira BioSciences, helps investors to forecast how Pacira stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pacira BioSciences, more accurately as focusing exclusively on Pacira BioSciences,'s fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Pacira BioSciences,'s intrinsic value based on its ongoing forecasts of Pacira BioSciences,'s financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Pacira BioSciences,'s closest peers.
Pacira BioSciences, Cash |
|
Pacira Valuation Trend
Analysing the historical paterns of Pacira BioSciences,'s enterprise value and its market capitalization is a good way to estimate and gauge the value of Pacira BioSciences, over time and is usually enough for investors to make rational market timing decisions.
Pacira Revenue by Product
Pacira BioSciences, Total Value Analysis
Pacira BioSciences, is at this time projected to have valuation of 1.26 B with market capitalization of 1.12 B, debt of 490 M, and cash on hands of 316.39 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Pacira BioSciences, fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.26 B | 1.12 B | 490 M | 316.39 M |
Pacira BioSciences, Investor Information
About 97.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.42. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pacira BioSciences, recorded a loss per share of 2.18. The entity had not issued any dividends in recent years. Based on the key measurements obtained from Pacira BioSciences,'s financial statements, Pacira BioSciences, is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Pacira BioSciences, Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pacira BioSciences, has an asset utilization ratio of 45.12 percent. This suggests that the Company is making $0.45 for each dollar of assets. An increasing asset utilization means that Pacira BioSciences, is more efficient with each dollar of assets it utilizes for everyday operations.Pacira BioSciences, Ownership Allocation
The majority of Pacira BioSciences, outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Pacira BioSciences, to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Pacira BioSciences,. Please pay attention to any change in the institutional holdings of Pacira BioSciences, as this could imply that something significant has changed or is about to change at the company.Pacira BioSciences, Profitability Analysis
The company reported the previous year's revenue of 700.97 M. Net Loss for the year was (99.56 M) with profit before overhead, payroll, taxes, and interest of 448.96 M.About Pacira BioSciences, Valuation
Our relative valuation model uses a comparative analysis of Pacira BioSciences,. We calculate exposure to Pacira BioSciences,'s market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pacira BioSciences,'s related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 701 M | 736 M | |
| Pretax Profit Margin | (0.09) | (0.09) | |
| Operating Profit Margin | (0.10) | (0.11) | |
| Net Loss | (0.14) | (0.15) | |
| Gross Profit Margin | 0.65 | 0.38 |
Pacira BioSciences, Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 46.2 M | |
| Quarterly Earnings Growth Y O Y | -0.381 | |
| Forward Price Earnings | 8.8028 |
Pacira BioSciences, Current Valuation Indicators
Valuation refers to the process of determining the present value of Pacira BioSciences, and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Pacira we look at many different elements of the entity such as Pacira's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Pacira BioSciences,, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Pacira BioSciences,'s valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Pacira BioSciences,'s worth.Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.